Breakthrough in Blood Cancer Treatment: Single-Dose CAR-T Shows Promise
TL;DR Summary
A new CAR-T immunotherapy developed by Legend Biotech and marketed by Johnson & Johnson has shown promising results in treating advanced multiple myeloma, with about a third of patients experiencing long-term remission, prompting discussions of a potential cure for this previously incurable blood cancer.
- A Blood Cancer Was Thought Incurable—Until Now Newser
- From No Hope to a Potential Cure for a Deadly Blood Cancer The New York Times
- Single-dose CAR-T therapy potentially curative in multiple myeloma Medical Xpress
- Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting Yahoo Finance
- Israeli researchers help achieve breakthrough in myeloma treatment Ynetnews
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
83%
265 → 44 words
Want the full story? Read the original article
Read on Newser